Shulian Wang1, Jeff Campbell2, Matthew H Stenmark3, Jing Zhao2, Paul Stanton2, Martha M Matuszak3, Randall K Ten Haken3, Feng-Ming Spring Kong4. 1. Department of Radiation Oncology, Georgia Regents University Cancer Center and Medical College of Georgia, Augusta, Georgia; Department of Radiation Oncology, Cancer Hospital and Cancer Institution, Chinese Academy of Medical Sciences, Beijing, China. 2. Department of Radiation Oncology, Georgia Regents University Cancer Center and Medical College of Georgia, Augusta, Georgia. 3. Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. 4. Department of Radiation Oncology, Georgia Regents University Cancer Center and Medical College of Georgia, Augusta, Georgia; Department of Radiation Oncology, Indiana University, Indianapolis, Indiana. Electronic address: fskong@iupui.edu.
Abstract
PURPOSE AND OBJECTIVES: We previously reported that the combination of mean lung dose (MLD) and inflammatory cytokines interleukin-8 (IL-8) and transforming growth factor-β1 (TGF-β1) may provide a more accurate model for radiation-induced lung toxicity (RILT) prediction in 58 patients with non-small cell lung cancer (NSCLC). This study is to validate the previous findings with new patients and to explore new models with more cytokines. METHODS AND MATERIALS: One hundred forty-two patients with stage I-III NSCLC treated with definitive radiation therapy (RT) from prospective studies were included. Sixty-five new patients were used to validate previous findings, and all 142 patients were used to explore new models. Thirty inflammatory cytokines were measured in plasma samples before RT and 2 weeks and 4 weeks during RT (pre, 2w, 4w). Grade ≥2 RILT was defined as grade 2, and higher radiation pneumonitis or symptomatic pulmonary fibrosis was the primary endpoint. Logistic regression was performed to evaluate the risk factors of RILT. The area under the curve (AUC) for the receiver operating characteristic curves was used for model assessment. RESULTS: Sixteen of 65 patients (24.6%) experienced RILT2. Lower pre IL-8 and higher TGF-β1 2w/pre ratio were associated with higher risk of RILT2. The AUC increased to 0.73 by combining MLD, pre IL-8, and TGF-β1 2w/pre ratio compared with 0.61 by MLD alone to predict RILT. In all 142 patients, 29 patients (20.4%) experienced grade ≥2 RILT. Among the 30 cytokines measured, only IL-8 and TGF-β1 were significantly associated with the risk of RILT2. MLD, pre IL-8 level, and TGF-β1 2w/pre ratio were included in the final predictive model. The AUC increased to 0.76 by combining MLD, pre IL-8, and TGF-β1 2w/pre ratio compared with 0.62 by MLD alone. CONCLUSIONS: We validated that a combination of mean lung dose, pre IL-8 level, and TGF-β1 2w/pre ratio provided a more accurate model to predict the risk of RILT2 compared with MLD alone.
PURPOSE AND OBJECTIVES: We previously reported that the combination of mean lung dose (MLD) and inflammatory cytokines interleukin-8 (IL-8) and transforming growth factor-β1 (TGF-β1) may provide a more accurate model for radiation-induced lung toxicity (RILT) prediction in 58 patients with non-small cell lung cancer (NSCLC). This study is to validate the previous findings with new patients and to explore new models with more cytokines. METHODS AND MATERIALS: One hundred forty-two patients with stage I-III NSCLC treated with definitive radiation therapy (RT) from prospective studies were included. Sixty-five new patients were used to validate previous findings, and all 142 patients were used to explore new models. Thirty inflammatory cytokines were measured in plasma samples before RT and 2 weeks and 4 weeks during RT (pre, 2w, 4w). Grade ≥2 RILT was defined as grade 2, and higher radiation pneumonitis or symptomatic pulmonary fibrosis was the primary endpoint. Logistic regression was performed to evaluate the risk factors of RILT. The area under the curve (AUC) for the receiver operating characteristic curves was used for model assessment. RESULTS: Sixteen of 65 patients (24.6%) experienced RILT2. Lower pre IL-8 and higher TGF-β1 2w/pre ratio were associated with higher risk of RILT2. The AUC increased to 0.73 by combining MLD, pre IL-8, and TGF-β1 2w/pre ratio compared with 0.61 by MLD alone to predict RILT. In all 142 patients, 29 patients (20.4%) experienced grade ≥2 RILT. Among the 30 cytokines measured, only IL-8 and TGF-β1 were significantly associated with the risk of RILT2. MLD, pre IL-8 level, and TGF-β1 2w/pre ratio were included in the final predictive model. The AUC increased to 0.76 by combining MLD, pre IL-8, and TGF-β1 2w/pre ratio compared with 0.62 by MLD alone. CONCLUSIONS: We validated that a combination of mean lung dose, pre IL-8 level, and TGF-β1 2w/pre ratio provided a more accurate model to predict the risk of RILT2 compared with MLD alone.
Authors: Matthew H Stenmark; Xu-Wei Cai; Kerby Shedden; James A Hayman; Shuanghu Yuan; Timothy Ritter; Randall K Ten Haken; Theodore S Lawrence; Feng-Ming Spring Kong Journal: Int J Radiat Oncol Biol Phys Date: 2012-10-01 Impact factor: 7.038
Authors: X L Fu; H Huang; G Bentel; R Clough; R L Jirtle; F M Kong; L B Marks; M S Anscher Journal: Int J Radiat Oncol Biol Phys Date: 2001-07-15 Impact factor: 7.038
Authors: Alena Novakova-Jiresova; Mieke M Van Gameren; Rob P Coppes; Harm H Kampinga; Harry J M Groen Journal: Radiother Oncol Date: 2004-05 Impact factor: 6.280
Authors: Katrien De Jaeger; Yvette Seppenwoolde; Harm H Kampinga; Liesbeth J Boersma; José S A Belderbos; Joos V Lebesque Journal: Int J Radiat Oncol Biol Phys Date: 2004-04-01 Impact factor: 7.038
Authors: Lujun Zhao; Kerby Sheldon; Ming Chen; Moli S Yin; James A Hayman; Gregory P Kalemkerian; Doug Arenberg; Susan E Lyons; Jeffrey L Curtis; Mary Davis; Kemp B Cease; Dean Brenner; Mitchell S Anscher; Theodore S Lawrence; Feng Ming Kong Journal: Lung Cancer Date: 2007-10-01 Impact factor: 5.705
Authors: Giulia Petroni; Lewis C Cantley; Laura Santambrogio; Silvia C Formenti; Lorenzo Galluzzi Journal: Nat Rev Clin Oncol Date: 2021-11-24 Impact factor: 66.675
Authors: Li Li; Henry Mok; Pavan Jhaveri; Mark D Bonnen; Andrew G Sikora; N Tony Eissa; Ritsuko U Komaki; Yohannes T Ghebre Journal: Expert Rev Anticancer Ther Date: 2018-07-23 Impact factor: 4.512
Authors: Feng-Ming Spring Kong; Lujun Zhao; Luhua Wang; Yuhchyau Chen; Jie Hu; Xiaolong Fu; Chunxue Bai; Li Wang; Theodore S Lawrence; Mitchell S Anscher; Adam Dicker; Paul Okunieff Journal: Transl Lung Cancer Res Date: 2017-12
Authors: Shulian Wang; Jeff Campbell; Matthew H Stenmark; Paul Stanton; Jing Zhao; Martha M Matuszak; Randall K Ten Haken; Feng-Ming Kong Journal: Radiother Oncol Date: 2018-03 Impact factor: 6.280
Authors: Yi Luo; Shruti Jolly; David Palma; Theodore S Lawrence; Huan-Hsin Tseng; Gilmer Valdes; Daniel McShan; Randall K Ten Haken; Issam Ei Naqa Journal: Phys Med Date: 2021-06-04 Impact factor: 3.119